Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism: Results of an International Survey from the I-DSD Registry by Stancampiano, Marianna R et al.








Testosterone Therapy and Its Monitoring in Adolescent Boys with
Hypogonadism: Results of an International Survey from the I-DSD Registry
Stancampiano, Marianna R ; Lucas-Herald, Angela K ; Bryce, Jillian ; Russo, Gianni ; Barera, Graziano
; Balsamo, Antonio ; Baronio, Federico ; Bertelloni, Silvano ; Valiani, Margherita ; Cools, Martine ;
Tack, Lloyd J W ; Darendeliler, Feyza ; Poyrazoglu, Sukran ; Globa, Evgenia ; Grinspon, Romina ;
Hannema, Sabine E ; Hughes, Ieuan A ; Tadokoro-Cuccaro, Rieko ; Thankamony, Ajay ; Iotova, Violeta
; Mladenov, Vilhelm ; Konrad, Daniel ; Mazen, Inas ; Niedziela, Marek ; Kolesinska, Zofia ;
Nordenström, Anna ; Ahmed, S Faisal
Abstract: It is unclear whether testosterone replacement therapy (TRT) in adolescent boys, affected by
a range of endocrine diseases that may be associated with hypogonadism, is particularly common. The
aim of this study was to assess the contemporary practice of TRT in boys included in the I-DSD Registry.
All participating centres in the I-DSD Registry that had boys between 10 and 18 years of age and with
a condition that could be associated with hypogonadism were invited to provide further information in
2019. Information on 162 boys was collected from 15 centres that had a median (range) number of 6 boys
per centre (1.35). Of these, 30 (19%) from 9 centres were receiving TRT and the median (range) age at
the start was 12.6 years (10.8–16.2), with 6 boys (20%) starting at x3c;12 years. Median (range) age of
boys not on TRT was 11.7 years (10.7–17.7), and 69 out of 132 (52%) were x3c;12 years. TRT had been
initiated in 20 of 71 (28%) boys with a disorder of gonadal development, 3 of 14 (21%) with a disorder
of androgen synthesis, and all 7 (100%) boys with hypogonadotropic hypogonadism. The remainder who
did not have TRT included 15 boys with partial androgen insensitivity, 52 with non-specific XY DSD,
and 3 with persistent Müllerian duct syndrome. Before starting TRT, liver function and blood count
were checked in 19 (68%) and 18 boys (64%), respectively, a bone age assessment was performed in 23
(82%) and bone mineral density assessment in 12 boys (43%). This snapshot of contemporary practice
reveals that TRT in boys included in the I-DSD Registry is not very common, whilst the variation in
starting and monitoring therapy is quite marked. Standardisation of practice may lead to more effective
assessment of treatment outcomes.
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Abstract
It is unclear whether testosterone replacement therapy (TRT) in 
adolescent boys, affected by a range of endocrine diseases that 
may be associated with hypogonadism, is particularly com-
mon. The aim of this study was to assess the contemporary 
practice of TRT in boys included in the I-DSD Registry. All par-
ticipating centres in the I-DSD Registry that had boys between 
10 and 18 years of age and with a condition that could be as-
sociated with hypogonadism were invited to provide further 
information in 2019. Information on 162 boys was collected 
from 15 centres that had a median (range) number of 6 boys 
per centre (1.35). Of these, 30 (19%) from 9 centres were receiv-
ing TRT and the median (range) age at the start was 12.6 years 
(10.8–16.2), with 6 boys (20%) starting at <12 years. Median 
(range) age of boys not on TRT was 11.7 years (10.7–17.7), and 
69 out of 132 (52%) were <12 years. TRT had been initiated in 
20 of 71 (28%) boys with a disorder of gonadal development, 3 
of 14 (21%) with a disorder of androgen synthesis, and all 7 
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
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(100%) boys with hypogonadotropic hypogonadism. The re-
mainder who did not have TRT included 15 boys with partial 
androgen insensitivity, 52 with non-specific XY DSD, and 3 with 
persistent Müllerian duct syndrome. Before starting TRT, liver 
function and blood count were checked in 19 (68%) and 18 
boys (64%), respectively, a bone age assessment was per-
formed in 23 (82%) and bone mineral density assessment in 12 
boys (43%). This snapshot of contemporary practice reveals 
that TRT in boys included in the I-DSD Registry is not very com-
mon, whilst the variation in starting and monitoring therapy is 
quite marked. Standardisation of practice may lead to more ef-
fective assessment of treatment outcomes.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Hypogonadism in adolescent boys may be due to sev-
eral diseases [Dwyer et al., 2015], and hormone replace-
ment therapy with testosterone (T) is considered one of 
the cornerstones of the clinical management. In a routine 
tertiary hospital setting in the United Kingdom, approxi-
mately 10–15% of boys reviewed for suspected hypogo-
nadism may proceed to testosterone therapy [Lucas-Her-
ald et al., 2018]. In childhood, the majority of children 
with suspected DSD are raised as boys [Rodie et al., 2011], 
and within a routine clinical setting it is estimated that a 
quarter of the boys with DSD may have biochemical evi-
dence of hypogonadism [Nixon et al., 2017]. Given that a 
child with XY DSD and profound hypogonadism is more 
likely to be raised as a boy nowadays [Kolesinska et al., 
2014], it is increasingly likely that there will be more hy-
pogonadal boys who will require androgen replacement 
in the future. However, currently, unlike girls, there is a 
relative lack of guidance on sex steroid replacement in af-
fected boys who are reaching the age of puberty [Bertel-
loni et al., 2008; Stancampiano et al., 2019].
In the absence of clear guidelines for testosterone ther-
apy in boys, the relative rarity of this indication, especial-
ly in boys with a DSD and some evidence of variations in 
practice [Lucas-Herald et al., 2018], there is a need to un-
derstand the current practice in more detail. Registered 
users of the I-DSD Registry have previously participated 
in surveys of practice [Kyriakou et al., 2016]. Therefore, 
to understand the variations in practice at an internation-
al level, I-DSD centres that had registered boys of a pu-
bertal age with a range of endocrine diseases that may be 
associated with hypogonadism were approached and in-
vited to participate in a survey of contemporary practice 
with regard to testosterone replacement therapy.
Patients and Methods
Between February and May 2019, those centres that had regis-
tered patients in the I-DSD Registry who were male, between the 
ages of 10 and <19 years, and who had a condition that could be 
associated with hypogonadism were approached to participate in 
an electronic survey. At the time of the study, there were a total of 
1,144 cases categorised as male in the I-DSD Registry, and of these, 
225 boys (20%) from 29 centres were within the suitable age band 
for inclusion. Of the 29 centres that were approached, 14 (48%) 
centres with a total of 174 boys (77%) agreed to participate, and of 
these, follow-up data were available in 127 (73%). In addition to 
these 127 boys, routinely collected clinical data on a further 35 boys 
were available from an additional centre, providing a total of 162 
cases from 15 centres. The median (range) number of boys per 
centre was 6 (1–35).
The questionnaire that was used to collect study data was di-
vided in 2 sections. The first section obtained information on year 
of birth (YOB), disorder type, diagnosis, karyotype, gonadectomy, 
and testosterone replacement therapy (TRT) status. Testosterone 
therapy received in infancy or topical dihydrotestosterone therapy 
on  genitalia were not regarded as TRT. As the I-DSD Registry did 
not collect the date of birth to estimate the age of each boy at the 
time of recruitment, all cases were assigned an arbitrary birthday 
of July, 1st. The second section of the questionnaire was reserved 
for the subset of patients who were on TRT, and this questionnaire 
collected information on age at starting hormone therapy, type of 
therapy, route of administration, dosage, length of treatment, and 
occurrence of adverse events during testosterone treatment. In ad-
dition, the centres were asked to report on any investigations per-
formed at initiation and during therapy. This included auxology, 
Tanner stage, FSH, LH, testosterone, SHBG, AMH, inhibin B, full 
blood count, liver function tests, bone mineral density, bone age, 
sperm count, metabolic, glucose, and bone profile.
The I-DSD Registry is an international database of pseudo-an-
onymized information deposited by clinicians following informed 
consent from the patient or their guardian. Details of the develop-
ment of the Registry and its recent use have been previously re-
ported [Ahmed et al., 2010; Ali et al., 2019], and its standard oper-
ating protocol is available at idsdorg.files.wordpress.com/2019/09/
the-i-dsd-i-cah-registry-data-access-policy-v1-290719-1.docx 
(last accessed, April 9, 2020). The Registry is approved by the Na-
tional Research Ethics Service in the UK as a research database of 
information that is collected as part of routine clinical care. Statis-
tical analysis was performed using GraphPad software package 
(Prism 8 for macOS version 8.0.2, GraphPad Software Inc, San 
Diego, CA, USA). All data were described as median and range, 
and comparison of continuous variables was performed using the 




The study cohort of 162 boys included 71 (44%) cases 
of a disorder of gonadal development (DGD), 15 (9%) 
cases of a disorder of androgen action (DAA), 14 (9%) 




cases of a disorder of androgen synthesis (DAS), 7 (4%) 
cases of hypogonadotropic hypogonadism, 3 (2%) cases 
of persistent Müllerian duct syndrome (PMDS), and 52 
(32%) cases of non-specific XY DSD (Table 1). The me-
dian age (range) of the entire population was 12.7 years 
(10.7–17.7). Among the 71 boys with a DGD, 29 (41%) 
had partial gonadal dysgenesis (PGD), 19 (27%) had 
Klinefelter syndrome, 12 (17%) had gonadal regression, 7 
(10%) had ovotesticular DSD, and the remaining 4 (5%) 
included 3 boys with XX testicular DSD and 1 boy with 
mixed gonadal dysgenesis. All cases of DGD were con-
firmed by one or more diagnostic methods, including 
biochemistry, genetics, and gonadal histology. All 15 boys 
with a DAA were diagnosed as partial androgen insensi-
tivity syndrome (PAIS) with a confirmed pathogenetic 
variant in the androgen receptor gene. Among the 14 
boys with a DAS, 7 (50%) had 5α-reductase deficiency, 3 
(21%) had isolated 17,20-lyase deficiency or combined 
with 17α-hydroxylase deficiency, 2 (14%) had 
3β-hydroxysteroid dehydrogenase deficiency, and there 
was 1 boy each with P450 oxidoreductase deficiency and 
17β-hydroxysteroid dehydrogenase type 3 deficiency. All 
these cases were confirmed by biochemistry and/or ge-
netic investigations. The initial presenting features among 
the 52 boys with non-specific XY DSD included a combi-
nation of genital anomalies with a total external mascu-
linisation score (EMS) [Ahmed et al., 2000] of <9 out of 
12 in 29 (56%) boys, isolated proximal hypospadias in 12 
(31%) boys, complex genital anomalies in 6 (15%), and 
isolated bilateral undescended testes in 1 boy.
Testosterone Replacement Therapy
Of the 162 boys, 30 (19%) were receiving TRT at the 
time of the study (Table 1), and these boys were from 9 
centres from 9 countries. Of these 30 boys, 24 (80%) 
from 9 centres had data available at follow-up. The me-
Table 1. Diagnoses in 162 boys with DSD aged 10–18 years in the I-DSD Registry and details of those on testosterone replacement therapy 
(TRT)
Disorder type Diagnosis Total n Boys on 
TRT (%)
Age at start of TRT, 
years, median 
(range)
Age of boys not on 
TRT, years, median 
(range)
Disorder of gonadal development Partial gonadal dysgenesis 29 3 (10) 12.5 (12.1–14.6) 12.2 (10.7–17.7)
Klinefelter syndrome 19 3 (16) 15.7 (13.3–16.2) 12.7 (10.7–17.7)
Gonadal regression 12 10 (83) 12.0 (10.8–14.7) 15.2 (12.7–17.7)
Ovotesticular DSD 7 4 (57) 14.5 (13.8–15.1) 11.7 (10.7–13.7)
Testicular DSD 3 – – 13.7 (11.7–13.7)
Mixed gonadal dysgenesis 1 – – 10.7
Total 71 20 (28)
Disorders of androgen synthesis 5α-reductase type 2 deficiency 7 – – 11.7 (10.7–15.7)
3β-hydroxysteroid dehydrogenase deficiency 2 1 (50) 11.5 (NA) 17.7 (NA)
17,20-lyase deficiencya 3 2 (67) 12.5 (12–13) 11.7* (NA)
P450 oxidoreductase deficiency 1 – – 10.7 (NA)
17β-hydroxysteroid dehydrogenase type 3 deficiency 1 – – 12.7 (NA)
Total 14 3 (21)
Disorders of androgen action Partial androgen insensitivity syndrome 15 0 – 10.7 (10.7–14.7)
Hypogonadotropic hypogonadism Isolated hypogonadotropic hypogonadism 2 2 (100) 13.6 (12.8–14.5) –
CHARGE syndrome 2 2 (100) 12.7 (12.5–13.0) –
DAX1 variant 2 2 (100) 12.9 (11.8–13.9) –
Allgrove syndrome 1 1 (100) 13.3 (NA)
Total 7 7 (100)
Non-specific DSDb Non-specific DSD with EMS <9 29 – – 11.7 (10.7–17.7)
Isolated hypospadias 12 – – 13.2 (10.7–17.7)
Complex genital anomalies 6 – – 14.2 (10.7–16.7)
Non-specific DSD with EMS ≥9 4 – – 12.7 (10.7–16.7)
Isolated undescended testes 1 – – 11.7 (NA)
Total 52 0
Other Persistent Müllerian duct syndrome 3 0 – 14.7 (14.7–16.7)
a Includes one boy with combined 17α-hydroxylase/17, 20-lyase deficiency. b Non-specific DSD are cases that were not identified as having hypogonad-
otropic hypogonadism, a disorder of gonadal development, a disorder of androgen synthesis, or a disorder of androgen action. NA, not applicable.
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dian (range) age at the start of TRT was 12.6 years (10.8–
16.2), and the median age at last assessment was 15.6 
years (12–17.5). Median (range) age of boys not on TRT 
was 11.7 years (10.7–17.7), and 69 out of 132 (52%) were 
<12 years. Of the 30 boys, 6 (20%) started TRT before 
the age of 12 years: 4 with gonadal regression, 1 with 
3β-hydroxysteroid dehydrogenase deficiency, and 1 
with hypogonadotropic hypogonadism (Fig.  1). All 
those with hypogonadotropic hypogonadism were on 
TRT, and a substantial proportion of those with DGD (n 
= 20; 28%) and DAS (n = 3; 21%) were also on TRT (Ta-
ble 1). However, none of the boys with PAIS, PMDS, or 
non-specific XY DSD were on TRT. Among the 15 boys 
diagnosed with PAIS, EMS at first presentation was 
available in 14, and 12 of these (86%) had an EMS ≥5. 
The 3 boys with PGD who had started TRT included 2 
who had undergone bilateral gonadectomy. There were 
another 2 boys with PGD with a median age of 11.7 years 
who had bilateral gonadectomy prepubertally and who 
had not started TRT at the time of study. The median 
age at starting therapy was broadly similar in the 3 sub-
groups of disorders (Fig. 1). However, the extent of vari-
ation in age at starting therapy was greater for those with 
DGD, and this was primarily because this group con-
sisted of boys with gonadal regression who started at a 
younger age (Fig. 1).
Testosterone Formulation
The formulation of testosterone the 30 boys were start-
ed on included Sustanon®, a blend of intramuscular tes-
tosterone esters (T decanoate 40%, T phenylproprionate 
24%, T isocaproate 24%, T proprionate 12%) in 14 (47%) 
patients, intramuscular testosterone enanthate in 12 
(40%), oral testosterone undecanoate in 2 (7%), and 
transdermal 2% testosterone gel in 2 (7%). Of the 24 boys 
who had follow-up data, 10 (42%) were on intramuscular 
Sustanon®, 8 (33%) were on intramuscular testosterone 
enanthate, and 6 (25%) were on transdermal 2% testos-
terone gel. One boy who was originally on oral testoster-
one undecanoate changed to intramuscular Sustanon®, 
1 changed from intramuscular Sustanon® to intramuscu-
lar testosterone enanthate, and 5 boys who were on intra-
muscular testosterone enanthate changed to transdermal 
2% testosterone gel; these 5 boys were all at 1 centre.
Monitoring of Therapy
Before starting treatment, liver function and blood 
count were checked in 19 (68%) and 18 boys (64%), re-
spectively. In addition, at start of therapy a radiological 
assessment of skeletal age was performed in 23 boys 
(82%), and an assessment of bone mineral density (BMD) 
was performed by dual energy X-ray absorptiometry in 
12 boys (43%). In the 24 boys with follow-up data, serum 














































Fig. 1. a Median age (and range) at the start of testosterone (T) treatment according to disorder type. b Median 
age (and range) at the start of T treatment according to diagnosis. DGD, disorders of gonadal development; HH, 
hypogonadotropic hypogonadism; DAS, disorders of androgen synthesis; GR, gonadal regression; OT-DSD, ovo-
testicular DSD; PGD, partial gonadal dysgenesis; KS, Klinefelter syndrome; 3BHSD, 3β-hydroxysteroid dehydro-
genase deficiency; CS, charge syndrom.




monitored in 19 (79%), 16 (67%), and 15 boys (63%), re-
spectively, at either 12 or 18 monthly intervals. BMD had 
been performed in 8 boys (33%) at an interval of 24 
months. Adverse effects that were reported to be related 
to TRT included acne or oily skin in 3 boys, including 2 
on intramuscular testosterone esters blend and 1 on oral 
testosterone undecanoate, aggressive behaviour in 1 boy 
on intramuscular testosterone esters blend, pain on injec-
tion in 1 boy on intramuscular testosterone esters blend, 
and a self-limiting episode of testicular pain in 1 boy on 
oral testosterone undecanoate.
Discussion
The current study represents the largest survey of TRT 
in boys with hypogonadism due to DSD or hypogonado-
tropic hypogonadism. It was designed to obtain a snap-
shot of contemporary practice, and boys within an age 
bracket where they would be currently receiving TRT 
were selected.
The occurrence of hypogonadism in boys and men 
with XY DSD has rarely been studied in detail. On sys-
tematic investigation of all boys presenting to an expert 
clinic with atypical genitalia, it is estimated that about a 
quarter may have an endocrine abnormality that may 
predispose them to long-term hypogonadism [Nixon et 
al., 2017]. However, it is possible that in some cases, hy-
pogonadism may not be present in early childhood but 
develops over time with spontaneous testicular degenera-
tion such as that observed in disorders of gonadal devel-
opment associated with NR5A1-related partial gonadal 
dysgenesis [Tantawy et al., 2012] or Klinefelter syndrome. 
In some conditions such as undescended testes, hypogo-
nadism may not be evident until adulthood [Rohayem et 
al., 2017] or may present after a procedure such as orchi-
dopexy [Tseng et al., 2019]. Single-centre studies of ado-
lescents suggest that in conditions such as partial gonad-
al dysgenesis, the occurrence of hypogonadism that pres-
ents overtly as pubertal delay may be as common as 40% 
[Gomes et al., 2018].
In the current study that included 15 centres, about a 
fifth of adolescent boys with a range of conditions were 
hypogonadal to such an extent that they required testos-
terone therapy for induction and maintenance of puber-
ty. Within this large group of diverse conditions, about a 
quarter of those with a disorder of gonadal development 
or disorder of androgen synthesis were on testosterone. 
In addition, all boys who had hypogonadotropic hypogo-
nadism were also on testosterone therapy. This latter 
finding is interesting to note given that opinion varies 
amongst specialists on whether to induce puberty with 
gonadotropins or testosterone [Han and Bouloux, 2010]. 
It is also possible that the availability of gonadotropins 
and the priority placed on fertility outcomes may have 
also influenced the therapeutic rationale. It was also im-
portant to note that none of the adolescents with PAIS 
were on testosterone therapy, and neither were those that 
had non-specific XY DSD who had normal gonadal func-
tion. Previous studies suggest that in adolescence, TRT 
may only be required by those who are severely under-
masculinized as described by an EMS  <5 [Lek et al., 
2018]; most of the cohort in the current study had a great-
er EMS. Interestingly, in young adulthood, almost 50% of 
men with PAIS with a wide range of EMS receive testos-
terone supplementation [Lucas-Herald et al., 2016]. The 
findings of these studies in combination suggest that an-
drogen supplementation in PAIS is more likely to be ini-
tiated for pubertal induction in boys who are particularly 
undermasculinised at first presentation, while a greater 
proportion of men with PAIS receive TRT in adulthood, 
perhaps for inadequate virilisation.
Whilst the age at starting TRT has been reported to be 
as low as 12 years in cases of permanent hypogonadism 
[Lucas-Herald et al., 2018], a fifth of the boys in the cur-
rent cohort had initiation of therapy at an age <12 years 
and as early as 10 years. The practice of starting testoster-
one as early as 10 years was particularly evident in boys 
with gonadal regression. Given that there is unequivocal 
evidence of primary hypogonadism in these cases and the 
mean age for genital stage 2 has been reported in some 
population studies to be as young as 9.5 years [Herman-
Giddens et al., 2001], there is a possible rationale for start-
ing testosterone early. However, most studies show that 
the age of attainment of genital stage 2 is between 11 and 
12 years [Juul et al., 2006]. Some who are concerned about 
pubertal growth have suggested that TRT should be initi-
ated after a bone age of 10.5 years [Mason et al., 2020]. In 
conditions other than bilateral anorchia or gonadal re-
gression, it is possible that the adolescent may have a state 
of partial hypogonadism where onset and/or progression 
through puberty may be affected to a variable extent. In 
such cases, it would be appropriate to monitor growth 
and pubertal development as well as biochemical markers 
of puberty and wait until there are clear signs that indicate 
that normal pubertal progress is unlikely to occur. It is 
likely that the timing of starting TRT is linked to the di-
agnosis, but to analyse this relationship, there is a need to 
study a larger group of boys with specific and confirmed 
diagnoses. The largest homogenous group of boys in the 
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current study who had TRT was the group of boys with 
gonadal regression, a condition which uniformly presents 
at a very early age. However, even in this group, the range 
of starting therapy was highly variable, ranging between 
10.8 and 14.7 years. There is a need to gain further struc-
tured evidence of the rationale for the starting age of tes-
tosterone therapy as well as its relative benefits and harms.
It is clear that despite the availability of oral and topical 
forms of testosterone [Stancampiano et al., 2019], the in-
tramuscular depot for testosterone remains the most 
popular form of therapy, confirming literature data [Dro-
bac et al., 2006]. However, it was interesting to note that 
over time, the topical form of testosterone may be gaining 
popularity and there may be differences between centres. 
Comparison of different forms of testosterone therapy 
have rarely been performed [Ahmed et al., 2004; Chioma 
et al., 2018], and it is likely that the choice of preparation 
is based on local availability and preferences. However, in 
adult men with DSD, it seems that a greater proportion 
seem to be satisfied with non-parenteral forms of TRT 
[Nordenström et al., 2018]. Satisfaction with testosterone 
replacement has not been systematically assessed in ado-
lescents and, in addition to markers of clinical efficacy, 
would benefit from being routinely assessed in the future. 
Reports of adverse effects were infrequent, but given that 
the study assessed these retrospectively, it is unclear 
whether these are sought routinely and whether they in-
fluence practice. Testosterone therapy in transgender ad-
olescents has been associated with changes in metabolic 
parameters [Stoffers et al., 2019]. While it is possible that 
the likelihood of adverse effects of testosterone replace-
ment may depend on the underlying condition, as sug-
gested recently in a study of young men with thalassaemia 
[De Sanctis et al., 2019], there is a need to assess these ef-
fects systematically in all boys who embark on long-term 
testosterone replacement. Clinical trials of testosterone 
therapy that evaluate the efficacy and safety for pubertal 
induction are very rare [Stancampiano et al., 2019] and 
probably reflect the heterogeneity and the rarity of the 
conditions for which boys require TRT. Although it 
seems that liver function tests and haematology are as-
sessed in the majority, this was not universal practice. 
Previously, guidance on the topic of monitoring TRT in 
adolescence has been published [Bertelloni et al., 2010; 
Soliman et al., 2014], and these have been revised recent-
ly [Stancampiano et al., 2019]. However, our experience 
from the current multicentre study, as well as previous 
studies [Nahata et al., 2015; Lucas-Herald et al., 2018], 
suggests that this guidance is not universally followed. 
Perhaps, this may also reflect the lack of evidence that 
supports the need for routine monitoring, as may be the 
case for regular assessment of BMD [Stancampiano et al., 
2019]. In the absence of clinical trials and licensed forms 
of TRT, there is a need to standardize the monitoring of 
therapy of such infrequent practice and ensure system-
atic collection of real-world evidence.
For pragmatic reasons we chose to define hypogonad-
ism as those boys on testosterone therapy. In those pa-
tients with conditions such as gonadal regression or con-
genital hypogonadotropic hypogonadism, it is likely that 
TRT was started before they developed any actual bio-
chemical or physical signs of hypogonadism. However, in 
general, it is possible that the current study is an under-
estimate of the actual number of adolescents with hypo-
gonadism given that this condition is a very wide spec-
trum and can include patients with biochemical hypogo-
nadism [Grinspon et al., 2019]. The prevalence of overt 
or sub-clinical hypogonadism in boys has not been sys-
tematically studied to date. Rodie et al. [2011] reported 
that approximately 50 cases with suspected DSD may 
present per year for a population of approximately 3 mil-
lion. Considering that in 2019 the estimated number of 
boys aged 10–19 years in the same area was 30,000 and 
that 24 boys included in the study were recruited from 
West of Scotland (https://www.understandingglasgow.
com/indicators/population/trends/changing_age_struc-
ture, last accessed, May 2019), it could be considered that 
boys with DSD were well represented. However, this may 
not be valid for all centres, and there may have been some 
selection bias. It is also possible that clinicians may have 
chosen to report cases that were more severely affected or 
the centres that chose to participate or not to may have 
introduced a level of bias. However, the current study still 
represents the largest assessment of the contemporary 
practice of testosterone therapy in boys with a wide range 
of conditions that cause permanent hypogonadism. The 
results show that testosterone therapy in boys with DSD 
is not a common occurrence and that there is a wide ex-
tent of variation in practice. It is possible that this varia-
tion is due to multiple factors, such as the needs of the 
young person himself, the clinical outcomes that are con-
sidered important by the clinician, and the local availabil-
ity of drugs. The results also stress the need for ongoing 
studies to monitor practice and highlight the need for 
guidelines and standardized protocols that can be used at 
the initiation and during maintenance of long-term tes-
tosterone therapy. Whilst the I-DSD Registry remains a 
valuable resource of cases of DSD, the study has also high-
lighted the need for developing a specific module within 
the Registry that focuses on capturing relevant informa-




tion on TRT in a standardized manner. These protocols 
and resources will allow us to understand the rationale as 
well as the short- and long-term effects of TRT in boys 
with DSD.
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